NEW YORK (GenomeWeb News) — Rules-Based Medicine has won a grant from the National Cancer Institute to work with Correlogic Systems to develop biomarker panels for cancer detection, RBM said today.
The contract includes a Phase I fast-track component and a Phase II option that together amount to $1.15 million.
In the two phases of the project, RBM will develop and test quantitative multiplexed immunoassays that incorporate analytes that the two companies have identified as targets for use in ovarian cancer detection.
Correlogic also will expand its existing analytic platform to determine the value of incorporating 19 additional analytes into its assays. Meanwhile, RBM will add the 19 assays to its HumanMAP platform.
The two companies previously collaborated on making Correlogic’s OvaCheck diagnostic test for ovarian cancer.
"Our research will integrate additional biomarkers associated with ovarian cancer into the existing Correlogic panel with the aim of achieving sensitivity and specificity levels that can open this test to a wider population of women,” RBM CEO Craig Benson said in a statement.